The Truvada lawsuit is a mass product liability case in which roughly 24,000 people who took Truvada or other Gilead HIV medications containing tenofovir disoproxil fumarate (TDF) allege the company delayed release of a safer alternative drug, tenofovir alafenamide (TAF), for nearly a decade to protect its TDF patent profits, causing avoidable kidney and bone injuries. A separate federal group of about 2,625 claims reached a proposed $40 million settlement in June 2024, but the much larger California state case is on hold pending a California Supreme Court ruling expected by August 2026.1Gilead Sciences. Gilead Statement on Agreement in Principle to Resolve Federal TDF Litigation2King & Spalding. Duty to Innovate: California Supreme Court Questions Novel Product Liability Theory
The Drug and the Injuries
Truvada is a combination HIV pill approved by the FDA in August 2004 for treating HIV-1 and in July 2012 for pre-exposure prophylaxis (PrEP) in people at high risk of infection.3Drugs.com. Truvada FDA Approval History It shares its active ingredient, TDF, with several other Gilead medications named in the litigation: Viread, Atripla, Complera, and Stribild.4Drugwatch. Tenofovir Disoproxil Fumarate Lawsuits
Truvada’s FDA-approved label warns of new or worsening kidney impairment, including acute renal failure and Fanconi syndrome, along with decreases in bone mineral density and reported cases of osteomalacia linked to kidney damage from the drug.5FDA. Truvada Prescribing Information A large study of HIV-positive veterans found each year of TDF use independently raised the risk of proteinuria, rapid kidney function decline, and chronic kidney disease.6TheBodyPro. Weighing Risks of TDF/FTC PrEP Side Effects
The alternative drug at the center of the lawsuits, TAF, delivers the same antiviral compound at much lower doses through a metabolic pathway that concentrates it in target cells rather than the bloodstream. The Phase 3 DISCOVER trial found TAF users maintained better kidney function and bone mineral density than TDF users over 96 weeks, with both drugs preventing HIV infection at greater than 99% efficacy.7Springer. Comparative Safety of F/TDF and F/TAF in PrEP Users
What Plaintiffs Allege Gilead Did
The lawsuits do not claim Truvada is a defective drug. They claim Gilead was negligent by continuing to sell it for years after the company had reason to believe a safer version was possible.
According to court filings, Gilead began investigating TAF in the late 1990s and ran a Phase I/II human trial in 2002. In 2004, the company halted TAF development, stating publicly the drug was not “sufficiently different” from TDF to justify further investment.8Justia. Gilead Tenofovir Cases, A165558
Plaintiffs allege internal documents show a different motive. A September 2003 internal document, unearthed in discovery, reportedly outlined a plan to delay TAF’s release to maximize profits from TDF and extend Gilead’s patent-protected position in the HIV market.9The New York Times. Gilead HIV Drug Tenofovir The first TDF patent was set to expire in 2017; by holding TAF until closer to that date, the company could, in the words of the internal document, “substantially increase the period of time” that at least one of its HIV treatments remained under patent. Gilead’s own modeling reportedly estimated that TDF-based regimens would result in 16,000 excess deaths and 150,000 cases of kidney and bone injury over a nine-year period.10STAT News. Gilead Suit Patent Hopping HIV Treatment
Gilead resumed TAF research in 2010. The FDA approved the first TAF-based medicine in 2015, more than a decade after development was paused. In 2011, as research restarted, Gilead’s president reportedly described TAF as a “kinder, gentler” version of TDF.8Justia. Gilead Tenofovir Cases, A165558
Plaintiffs earlier dropped their strict liability and breach of warranty claims. What remains is ordinary negligence, alongside a fraudulent concealment claim that has since been narrowed on appeal.
Gilead’s Response
Gilead maintains that Truvada and its other TDF medicines are beneficial and non-defective, and that all potential side effects involving bones, kidneys, and teeth were fully and properly disclosed on the label.11Gilead Sciences. TDF Litigation
On the science, the company argues that the long-term safety of TAF was unknown in 2004. The only completed human study at that point involved 20 patients over 14 days and showed a similar safety profile to TDF. TAF had not advanced to Phase III trials, and Gilead says some early preclinical data suggested potential toxicity concerns for TAF itself.12Supreme Court of California. Gilead Supreme Court Reply Brief Five more years of research followed the 2010 restart before FDA approval.
Gilead also disputes the profit theory on its own terms: if TAF had been shown to be materially safer in 2004, the company argues, the most profitable path would have been to launch it immediately and maximize patent life on the newer drug, not shelve it.
Where the Cases Stand
The roughly 24,000 plaintiffs’ cases are coordinated in California state court under JCCP No. 5043.13FindLaw. Gilead Tenofovir Cases, JCCP No. 5043 A smaller group is consolidated in the Northern District of California federal court. No jury trial on the merits has occurred in either forum.4Drugwatch. Tenofovir Disoproxil Fumarate Lawsuits
On January 9, 2024, the California Court of Appeal issued a split ruling. On negligence, it affirmed the trial court’s refusal to give Gilead summary judgment, holding that a manufacturer’s duty of reasonable care can extend beyond the duty not to market a defective product. Plaintiffs can pursue the theory that Gilead was negligent in delaying TAF without needing to prove TDF itself was defective. On fraudulent concealment, the court sided with Gilead, ruling the company had no duty to disclose information about TAF to TDF users while TAF remained an unapproved alternative.8Justia. Gilead Tenofovir Cases, A165558
In May 2024, the California Supreme Court granted Gilead’s petition for review. The question before the court is whether California law imposes a duty on a manufacturer to continue researching and developing a different product that might turn out to be an improvement over what it already sells.11Gilead Sciences. TDF Litigation The appellate court grounded its ruling in California Civil Code Section 1714, which establishes a broad duty of care.14Holland & Knight. California Justices to Weigh Gilead Negligence Claim in HIV Suit Oral arguments were held on May 6, 2026. The court typically issues an opinion within 90 days of oral argument, so a ruling is expected by August 2026.2King & Spalding. Duty to Innovate: California Supreme Court Questions Novel Product Liability Theory
The ruling will effectively decide the case. If the court affirms, the coordinated proceeding involving 24,000 plaintiffs would move toward bellwether trials, the first jury tests of liability and damages. If it reverses, the legal foundation for the vast majority of the claims would collapse.
The $40 Million Federal Settlement
In June 2024, Gilead announced an agreement in principle to pay up to $40 million to resolve approximately 2,625 claims pending in the federal court litigation.1Gilead Sciences. Gilead Statement on Agreement in Principle to Resolve Federal TDF Litigation The proposed deal required at least 98% of eligible plaintiffs to participate for it to become final. For any who opted out, Gilead said it would continue to defend itself.15San Francisco Chronicle. Gilead Settlement
Payouts are expected to vary by injury severity, with cases involving kidney failure or long-term disability valued significantly higher than milder cases. Spread across eligible claimants, the fund works out to an average of roughly $12,500 per person for lower-severity cases after legal fees and participation, a figure some plaintiffs’ advocates have called modest.16Ethen Ostroff Law. Truvada Lawsuit Whether the 98% threshold was met and the settlement finalized is not confirmed in the available record.
The federal deal does not cover the far larger California state proceeding, which remains pending.
Who Can File a Truvada Lawsuit
The litigation covers people who took a Gilead-manufactured medication containing TDF and suffered a qualifying injury. The covered drugs are Truvada, Viread, Atripla, Complera, and Stribild.4Drugwatch. Tenofovir Disoproxil Fumarate Lawsuits
Qualifying injuries fall into two categories:
- Kidney injuries, including acute kidney injury, chronic kidney disease, Fanconi syndrome, and kidney tubular dysfunction.
- Bone injuries, including osteopenia, osteoporosis, and bone fractures.
As of 2026, attorneys are still accepting new cases. Whether an individual claim is timely depends on the statute of limitations in the applicable state and on when the injury was discovered. Cases have been filed in California, Missouri, Delaware, Florida, Louisiana, and New York, among other jurisdictions.
One boundary worth flagging: the separate antitrust litigation against Gilead, which produced a $246.8 million settlement with direct purchasers of HIV medications in January 2024, addressed wholesale pricing claims brought by insurers and health plans, not personal injuries.17Law360. In Re HIV Antitrust Litigation Individual patients who took Truvada and suffered kidney or bone injuries are not compensated through that settlement; their claims sit in the product liability track described above.
What to Watch Next
The California Supreme Court’s decision, expected by August 2026, is the pivot point. An affirmance opens the door to bellwether trials and, potentially, broader settlement discussions across the 24,000-plaintiff pool. A reversal would end most of the litigation. Anyone considering a claim should consult a product liability attorney promptly, because state-by-state deadlines continue to run regardless of how the appellate question is resolved.